Although the overall proportions of tumor-infiltrating CD45+ immune cells and CD45+CD11b+ myeloid cells remained unchanged between the two groups, Ulk1 KO-derived tumors showed a marked reduction in the proportion of neutrophils (CD45+CD11b+Ly6G+) and PMN-MDSCs (CD11b+Ly6G+F4/80−) compared with tumors derived from Ulk1 WT KPC cells, alongside a significant increase in major histocompatibility complex (MHC)-II+ antigen-presenting cells (APCs) (CD45+CD11b+ MHC-II+) in tumors derived from Ulk1 KO KPC cells (Fig. 6a,b). This evidence concerns the gene PTPRC and neoplasm.